Analyst Price Targets — CRL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 10:42 am | Luke Sergott | Barclays | $210.00 | $178.34 | TheFly | Charles River price target raised to $210 from $200 at Barclays |
| April 14, 2026 12:15 am | — | RBC Capital | $215.00 | $178.34 | TheFly | Charles River initiated with an Outperform at RBC Capital |
| February 20, 2026 12:29 pm | — | Mizuho Securities | $175.00 | $164.24 | TheFly | Charles River price target lowered to $175 from $215 at Mizuho |
| February 19, 2026 1:56 pm | Eric Coldwell | Robert W. Baird | $193.00 | $158.18 | TheFly | Charles River price target lowered to $193 from $231 at Baird |
| February 19, 2026 11:31 am | Luke Sergott | Barclays | $200.00 | $158.00 | TheFly | Charles River price target lowered to $200 from $215 at Barclays |
| January 13, 2026 1:33 pm | — | Robert W. Baird | $231.00 | $221.69 | TheFly | Charles River price target raised to $231 from $224 at Baird |
| January 13, 2026 12:54 pm | — | Evercore ISI | $260.00 | $225.11 | TheFly | Charles River price target raised to $260 from $250 at Evercore ISI |
| January 9, 2026 1:11 pm | Eric Coldwell | Robert W. Baird | $224.00 | $219.49 | TheFly | Charles River price target raised to $224 from $199 at Baird |
| January 9, 2026 12:08 pm | Ann Hynes | Mizuho Securities | $215.00 | $215.51 | TheFly | Charles River price target raised to $215 from $200 at Mizuho |
| December 18, 2025 12:06 pm | — | Mizuho Securities | $200.00 | $195.98 | TheFly | Charles River price target raised to $200 from $174 at Mizuho |
Latest News for CRL
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Massachusetts Financial Services Co. MA acquired a new stake in Charles River Laboratories International, Inc. (NYSE: CRL) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 884,691 shares of the medical research company's stock, valued at approximately $176,478,000. Massachusetts Financial Services Co.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with the American Heart Association, the world's leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives. “New data from the American Heart Association shows that cardiovascular…
Shares of Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 6, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.